Impact Factor: 7.883
Submit Paper
Volume 11, Issue 5 (May 2025)

Comparative Study Of Different Marketed Preparation

Impact Factor
7.883
Call For Paper
Volume 12 Issue 07

July 2026

Download Paper Format
Copyright Form
Share on:

Author(s)

B. D. TIWARI S. R. MASHALE T. S. PARDESHIMATH

Abstract

For The Treatment Of Acid Reflux Disease (GERD), Functional Dyspepsia, And Acid Reflux Disorders, Doctors Frequently Prescribe The Fixed-dose Combination (FDC) Of Omeprazole, A Proton Pump Inhibitor (PPI), And Dopamine D2 Receptor Antagonist, Domperidone, Which Has Prokinetic And Antiemetic Effects. By Enhancing Stomach Motility And Decreasing Gastric Acid Secretion At The Same Time, This Combination Has A Synergistic Therapeutic Effect. However, Due To Differences In Formulation Design, Enteric Coating Technologies, And Manufacturing Standards, Different Marketed Formulations Of This FDC May Have Different Pharmaceutical Quality And Therapeutic Consistency. These Variations May Have A Major Effect On The Release Of The Drug, Its Bioavailability, And Eventually Its Clinical Effectiveness.


Keywords

Paper ID

IJSARTV11I5103597

Publication Date

May 18, 2025

Research Area

NA

Submit Your Paper to IJSART

Join the global research community with IJSART. Submit your paper, share your work, and gain worldwide recognition!